Rosuvastatin: A review of its use in the management of dyslipidemia

American Journal of Cardiovascular Drugs

Volumn 4, Issue 2, 2004, Pages 117-138

  Scott, Lesley J ^a   Curran, Monique P ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; ERYTHROMYCIN; ETHINYLESTRADIOL PLUS NORGESTREL; FENOFIBRATE; FLUCONAZOLE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

ABDOMINAL PAIN; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DETERIORATION; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; DYSLIPIDEMIA; FLUSHING; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER CELL; MEDICAL DECISION MAKING; MULTICENTER STUDY; MYALGIA; MYOPATHY; NAUSEA; PATIENT EDUCATION; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

DRUG INTERACTIONS; FLUOROBENZENES; FOOD-DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; METABOLIC CLEARANCE RATE; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES;

EID: 2342599061     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404020-00005     Document Type: Review

References (101)

1. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62 (14): 2075-85; discussion 2086-7
2. Schuster H. Rosuvastatin: a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology 2003; 99 (3): 126-39
3. Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. JUPITER Study Group. Circulation 2003 Nov 11; 108 (19): 2292-7
4. Schuster H. I Study Group on behalf of the MERCURY, Effects of switching to rosuvastatin from atorvastatin or other statins on achievement of international low-density lipoprotein cholesterol goals: MERCURY I trial. J Am Coll Cardiol 2003 Mar 19; 41 Suppl. A: 227-8. Plus poster presented at 52nd Annual Scientific Session of the American College of Cardiology; 2003 Mar 30-Apr 2, Chicago
5. Schuster H, Cheung R, Bonnet J, et al. Switching to rosuvastatin from other statins has beneficial effects on lipid ratios [abstract no. 1P-0281]. Atheroscler Suppl 2003; 4 (2): 81
6. Stein EA, Jones PH, Rhyne JM, et al. Rosuvastatin improves apolipoproteins A-1 and B more than atorvastatin, sinivastatin, and pravastatin (STELLAR trial results) [abstract no. 2P-0585]. Atheroscler Suppl 2003; 4 (2): 168. Plus poster presented at the XIII International Symposium on Atherosclerosis; 2003 Sep 28-Oct 2, Kyoto
7. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, sinivastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 Jul 15; 92 (2): 152-60
8. Jones PH, Hunninghake DB, Ferdinand KC, et al. Statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR): non-high-density lipoprotein cholesterol results and goals [abstract no. P2362). Eur Heart J 2003; 24 Suppl.: 460
9. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19 (8): 689-98
10. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001 Mar 8; 87 (Pt 5A): 28B-32B
11. Holdgate GA, Ward WH, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003 Jun; 31 (Pt 3): 528-31
12. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002 Sep; 42 (9): 963-70
13. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells [abstract no. MoP29:W6]. Atherosclerosis 2000; 151 Suppl.: 41
14. Smith G, Davidson R, Bloor S, et al. Pharmacological properties of ZD4522 - a new HMG-CoA reductase inhibitor [abstract no. MoP20:W6]. Atherosclerosis 2000; 151: 39
15. Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyle pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997; 5 (2): 437-44
16. AstraZeneca. Crestor (rosuvastatin calcium): US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP, 2003
17. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002 Nov; 30 (11): 1158-63
18. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler Suppl 2002 Apr; 2 (4): 33-6; discussion 36-7
19. Brown CDA, Windass A, Bleasby K, et al. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract no. 166]. Atheroscler Suppl 2001; 2 (2): 88
20. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25 (9): 649-63
21. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003; 4 (1): 9-14
22. Martin PD, Mitchell PD, Schineck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002 Nov; 54 (5): 472-7
23. Cameron NE, Smith GJ, McTaggart F, et al. Effects of treatment with the statin, ZD4522, on peripheral nerve function and perfusion in diabetic rats [abstract]. Diabetologia 2000 Aug; 43 Suppl. 1: A50
24. Caslake MJ, Bedford D, Stewart G, et al. Rosuvastatin: kinetics of apo, B-containing lipoproteins in moderate hypercholesterolaemia [abstract no. 3P-0786]. Atheroscler Suppl 2003; 4 (2): 234
25. Prassl R, Caslake MJ, Packard CJ, et al. Rosuvastatin enhances lipid fluidity in atherogenic apoB-containing lipoproteins [abstract no. 528]. 73rd European Atherosclerosis Society Congress; 2002 7-10 Jul; Salzburg
26. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001; 88 (3): 291-3
27. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003; 24 (3): 225-48
28. Laufs U, Nickenig G, Bohm M, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, up-regulates endothelial nitric oxide synthase and protects from stroke in mice [abstract no. 2604]. Eur Heart J 2002; 23 Suppl.: 499
29. Laufs U, Bohm M, Gertz K, et al. The hydrophilic HMG-CoA reductase inhibitor rosuvastatin regulates endothelial NO synthase and ischaemic stroke in vivo [abstract no. 1370]. Circulation 2002; 106 (19 Suppl.): II272
30. Hermann M, Ruschitzka F, Camici G, et al. Rosuvastatin improves endothelial dysfunction in a rat model of normocholesterolemic mineralocorticoid hypertension. Hypertension 2002 Sep; 40: 439-40
31. Jones SP, Gibson MF, Rimmer III DM, et al. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002 Sep 18; 40 (6): 1172-8
32. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001 Jun; 133 (3): 406-12
33. Nangle MR, Cotter MA, Cameron NE. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 2003 Sep; 52 (9): 2396-402
34. Calhoun D, Dai S, Oparil C, et al. Rosuvastatin-induced modulation of NO-dependent superoxide formation [abstract no. 4P-1039]. Atheroscler Suppl 2003; 4 (2): 303
35. Pelat M, Dessy C, Massion P, et al. Altered blood pressure and heart rate variability in hypercholesterolemic apoE-/- mice is corrected by rosuvastatin independently of its plasma lipid lowering activity [abstract no. 4P-1061]. Atheroscler Suppl 2003; 4 (2): 308
36. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002 Oct 1; 22 (10): 1567-72
37. Kleemann R, Princen HM, Emeis JJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003 Sep 16; 108 (11): 1368-74
38. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003 Sep 17; 42 (6): 1091-7
39. Bellosta S, Monetti M, Canavesi M, et al. Rosuvastatin displays anti-atherothrombotic properties in apo-E deficient mice [abstract no. 4P-1081]. Atheroscler Suppl 2003; 4 (2): 312
40. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 2003 Apr; 41 (4): 649-56
41. Verhulst A, D'Haese PC, De Broe ME. Statins inhibit endocytosis in human proximal tubules [abstract]. J Am Soc Nephrol 2003; 14 Suppl.: 376A
42. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002 Oct; 42 (10): 1116-21
43. Warwick MJ, Dane AL, Raza A, et al. Pharmacokinetic and safety profile for the new HMG-CoA reductase inhibitor ZD4522 (single and multiple doses) [abstract no. 397]. Can J Cardiol 2000 Sep; 16 (Suppl. F): 196
44. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Therapeut 2003; 25 (10): 2553-63
45. Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003 Feb; 25 (2): 459-71
46. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003 Apr; 73 (4): 322-9
47. Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003 May; 59 (1): 51-6
48. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003 Jan; 55 (1): 94-9
49. Martin PD, Kemp J, Dane AL, et al. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002 Dec; 42 (12): 1352-7
50. Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002 Nov; 58 (8): 527-31
51. McCormick AD, McKillop D, Butters CJ, et al. ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract no. 46]. J Clin Pharmacol 2000 Sep; 40 (9): 1055
52. Martin PD, Dane AL, Schneck DW, et al. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract no. 48]. J Clin Pharmacol 2000 Sep; 40 (9): 1056
53. Simonson SG, Martin PD, Mitchell P, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003 Feb; 58 (10): 669-75
54. Prueksaritanout T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30 (11): 1280-7
55. AstraZeneca UK Limited. Crestor 40mg tablets [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Mar 8]
56. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001 Sep 1; 88 (5): 504-8
57. Saito Y, Gotto Y, Dane A, et al. Randomized, double-blind, placebo-controlled, dose-ranging study of rosuvastatin in Japanese hypercholesterolemic subjects [abstract no. 620]. Atheroscler Suppl 2002; 3 (2): 199. Plus poster presented at 73rd European Atherosclerosis Society Congress; 2002 Jul 7-10, Salzburg
58. Schneck DW, Knopp RH, Ballantyne CM, et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003 Jan 1; 91 (1): 33-41
59. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002 Dec; 144 (6): 1036-43
60. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002 Feb 1; 89 (3): 268-75
61. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Rosuvastatin Investigators Group. Am Heart J 2002 Dec; 144 (6): 1044-51
62. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001 Dec; 8 (6): 383-90
63. Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003 Mar 6; 91 (Pt 5A): 3-10C; discussion 10C
64. Grundy SM, Bilheimer D, Chait A, et al. Summary of the second report of the National Cholesterol Education Progam (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993; 269 (23): 3015-23
65. Grundy SM, Becker D, Clark LT, et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285 (19): 2486-97
66. Rader DJ, Davidson MH, Caplan RJ, et al. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003 Mar 6; 91 (Pt 5A): 20-23C; discussion 23-24C
67. Stein EA, Jones PH, Deedwania PC, et al. Rosuvastatin compared with atorvastatin, simvastatin, and pravastatin for lipid ratios (STELLAR trial results) [abstract no. 2P-0586]. Atheroscler Suppl 2003; 4 (2): 168
68. Shepherd J, Hunninghake DB, Barter P, et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003 Mar 6; 91 (Pt 5A): 11-17C; discussion 17-19C
69. Shepherd J, Packard C, Smith K, et al. Evaluation of rosuvastatin in the treatment of hypercholesterolaemia in postmenopausal women [abstract no. 340]. Atheroscler Suppl 2002; 3 (2): 205. Plus poster presented at 73rd European Atherosclerosis Society Congress; 2002 Jul 7-10, Salzburg
70. Marais D, Raal F, Stein E, et al. Effect of rosuvastatin on LDL-cholesterol, mevalonic acid and other lipid measurements in patients with homozygous familial hypercholesterolaemia [abstract no. 435]. Atheroscler Suppl 2002; 3 (2): 159. Plus poster presented at 73rd European Atherosclerosis Society Congress; 2002 Jul 7-10, Salzburg
71. Best JD, O'Neal DN. Diabetic dyslipidaemia: current treatment recommendations. Drugs 2000; 59 (5): 1101-11
72. Ballantyne CM, Stein EA, Paoletti R, et al. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003 Mar 6; 91 (Pt 5A): 25-27C; discussion 28C
73. Durrington P, Tuomilehto J, Hamann A, et al. Response to lipid-lowering treatment with rosuvastatin in diabetic patients with the metabolic syndrome [abstract no. P257]. Diabet Med 2003 Apr; 20 Suppl. 2: 100
74. Durrington P, Hamann A, Tuomilehto J, et al. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes [abstract no. 631]. Diabetologia 2001; 44 Suppl. 1: 165. Plus poster presented at 37th Annual Conference of the European Association for the Study of Diabetes; 2001 Sep 9-13, Glasgow
75. Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003 Jun 1; 91 (11): 1304-10
76. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92 Suppl.: 23-29K
77. Shepherd J, Kastelein J, Harris S, et al. Summary of the benefit-risk profile of rosuvastatin 10-40mg from an international clinical trial programme [abstract no. P14]. Circulation [online]. Available from URL: http://circ.ahajournals.org/cgi/content/full/107/19/e131 [Accessed 2003 May 20]
78. Clearfield M. Evolution of cholesterol management therapies: exploiting potential for further improvement. Am J Ther 2003; 10 (4): 275-81
79. Worz CR, Bottorff M. Treating dyslipidemic patients with lipid-modifying and combination therapies. Pharmacotherapy 2003; 23 (5): 625-37
80. Brown WV. Reaching goal: conquering the treatment gaps in dyslipidemia management. Clin Cardiol 2003; 26 (4 Suppl. 3): III1-2
81. LaRosa JC. Reduction of serum LDL-C levels: a relationship to clinical benefits. Am J Cardiovasc Drugs 2003; 3 (4): 271-81
82. Cheng-Lai A. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis 2003; 5 (1): 72-8
83. Gotto AM Jr. Treating hypercholesterolemia: looking forward. Clin Cardiol 2003; 26 (1 Suppl. 1): I21-8
84. Darkes MJM, Poole RA, Goa KL. Ezetimibe. Am J Cardiovasc Drugs 2003; 3 (1): 67-76
85. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002; 11 (11): 1587-604
86. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003; 4 (5): 779-90
87. Stein EA. Management of dyslipidemia in the high-risk patient. Am Heart J 2002 Dec; 144 (6 Suppl.): S43-50
88. Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003; 145 (3): 387-96
89. Hvizdos KM, Goa KL. Management of dyslipidaemias: the role of simvastatin. Dis Manage Health Outcomes 2000; 7 (2): 83-109
90. McKenney JM. New cholesterol guidelines, new treatment challenges. Pharmacotherapy 2002 Jul; 22 (7): 853-63
91. Chong PH. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann Pharmacother 2002 Dec; 36 (12): 1907-17
92. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20 (4): 303-28
93. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-9
94. Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998; 339 (19): 1349-57
95. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Eng J Med 1996; 335 (14): 1001-9
96. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279 (20): 1615-22
97. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Eng J Med 1995; 333 (20): 1301-7
98. Palmer SJ, Brady AJ, Ratcliffe AE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract 2003; 57 (9): 792-800
99. James M, Hirsch M, Jones P. Cost-effectiveness of rosuvastatin: a pharmacoeconomic analysis of statin dose comparisons in the STELLAR trial [abstract no. 2P-0595]. Atheroscler Suppl 2003; 4 (2): 170
100. Brown J, Schuster H, James M. Rosuvastatin is cost-effective compared with other statins: pharmacoeconomic analysis of MERCURY 1 [abstract no. 2P-0594]. Atheroscler Suppl 2003; 4 (2): 170
101. James M, Brown J, Schuster H. Switching patients to rosuvastatin from atorvastatin or other statins is cost-effective: pharmacoeconomic analysis of MERCURY I [abstract no. PCV46]. Values Health 2003; 6 (6): 660-1